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Abstract
Background. Beta thalassemia major (BT) is an inherited blood disorder caused by reduced or absent syn-
thesis of the hemoglobin beta chains, associated with profound anemia, jaundice, splenomegaly, expanded 
bone marrow volume, siderosis and cardiomegaly. Because of repeated blood transfusions, BT patients are 
subjected to peroxidative tissue injury due to secondary iron overload.
Objectives. The aim of the study was to analyze: 1) the total antioxidant capacity (TAC) value in BT patients 
(study group) and their healthy controls (control group) from Greece (Central Macedonia) and Italy (Sar-
dinia); correlations between 2) the TAC and ferritin levels of BT patients, and 3) the TAC and ferritin values in 
BT patients with different chelation therapies;
Material and methods. The studied group consisted of 60 subjects diagnosed with BT (41 female, 
mean age: 41.5 ± 9.5 years) and 40 healthy controls matched with age and sex (31 female, mean age: 
38.5 ± 3.7 years). Desferrioxamine (DFO) was the basic previous chelation regimen for all BT patients. Anti-
oxidant activity was assayed spectrophotometrically, using a TAC Kit (Total Antioxidant Capacity Colorimet-
ric assay kit, produced by Cayman Chemical Co.), and ferritin was assayed by immunoturbidimetry.
Results. Lower levels of TAC were observed in BT patients of both countries when compared with controls 
(1.83 mmol/L vs 2.7 mmol/L in the Italian study group and controls and 2.42 mmol/L vs 3.2 mmol/L in 
the Greek study group and controls). There were no significant correlations between plasmatic TAC and 
ferritin. Furthermore, deferasirox was the only chelation treatment in which TAC showed a correlation in 
both regions.
Conclusions. Our results potentially suggest that the reduced levels of TAC detectable in BT patients could 
demonstrate their reduced antioxidant defensive mechanisms.
Key words: oxidative stress, β-thalassemia major, total antioxidant capacity, chelation therapies, Mediter-
ranean countriesDOI
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Transfusion practice and chelation therapy are the 
cornerstones of the modern clinical management of pa-
tients with beta thalassemia (BT) major, and have sub-
stantially contributed to improving the outcomes in such 
patients.1 Nevertheless, iron overload remains a common 
complication, especially after long-term treatment.2,3 On 
the one hand, it has been evident from previous studies 
that iron overload is the main causative agent responsible 
for the increased production of free radicals and reac-
tive oxygen species (ROS), and the subsequent oxidative 
stress which is compensated for by various antioxidants 
present in the body.4 Oxidative stress occurs as a result of 
increased levels of lipid peroxides and free-radical inter-
mediates, along with a decrease in total antioxidant ca-
pacity (TAC).5 On the other hand, the selection of proper 
iron chelatory agents can be helpful in the regulation of 
the antioxidant status in patients with BT major. Cur-
rently, there are 3 main iron-chelating agents available 
for continuous use in patients with thalassemia on regu-
lar transfusions, i.e. desferrioxamine (DFO), deferiprone 
(DFP) and deferasirox (DFX), which provide good results 
in reducing cardiac, hepatic and endocrine toxicity.6 His-
torically, the most widely-used chelator is DFO, which 
demonstrated a significant reduction in the morbidity 
and mortality of these patients by preventing or reduc-
ing the damage to key organs such as the heart, liver and 
endocrine glands. Two new-generation chelators such as 
DFP and DFX, which can be administered orally, have 
substantially improved compliance and quality of life of 
these patients.7 Oxidative stress and disturbances in the 
antioxidant balance have been studied extensively in BT 
major patients.8–11 The main purpose of this study was to 
investigate if there is any correlation between the plas-
matic TAC and ferritin blood levels in BT patients of 2 
Mediterranean regions such as Central Macedonia and 
Sardinia. We also evaluated the possible impact of differ-
ent iron chelators in this setting.
Material and methods
Patients and controls
Table 1 has all the demographical and clinical char-
acteristics of the study and control groups. Sixty 
β-thalassemic major individuals were included in the 
study: 30 Italian patients from Sardinia (group A, Ser-
vizio Trasfusionale, Ospedale Santissima Annunziata, 
Sassari), and 30 Greek patients from Central Macedonia 
(group B, Saint Paul General Hospital of Thessaloniki, 
Greece). The mean age of the patients was 42 and 41 
(range 25–65) years in the 2 groups, respectively. There 
were 19 (63%) females in group A (Italians) and 22 (73%) 
in group B (Greeks). All subjects had given informed con-
sent. The diagnosis of β-thalassemia major was made 
considering the results of hemoglobin electrophoresis 
and the clinical features of the patients. BT minor and 
intermediate cases were excluded. In addition, 26.6% of 
the study group was represented by healthy carriers of 
HCV. The Italian and Greek patients were receiving an 
average dosage of iron chelators of 74/5 mg/Kg and 66.6 
mg/kg, respectively, while they had been under chelation 
therapy for an average of 33.5 and 37.1 years, respectively. 
All the patients who underwent long-lasting transfusion 
therapy were under chelation therapy with one or more 
of the following medications: DFX, DFP or DFO. Six sub-
groups were considered in relation to the treatment mo-
dality, group A1 for the Italian study group using DFX 
(71% female, mean age: 42.8 ± 12.8 years); A2 for those 
using DFP (85% female, mean age: 39.3 ± 10 years ); A3 
for the Italian BT patients using DFO (50% female, mean 
age: 43.7 ± 4.6 years); and A4 for those under DFX + DFO 
(50% female, mean age: 42.85 ± 7.7 years) chelation treat-
ment. The Greek study group B1 for the patients using 
DFX (72.7% female, mean age: 44  ±  10.3 years) and B2 
for those chelating with DFP (73.6% female, mean age: 
37 ± 7.3 years). Forty age- and sex-matched healthy sub-
jects were enrolled in the study: 20 Italians (75% female, 
mean age: 38.75 ± 3.8 years) from Sardinia and 20 Greeks 
(80% female, mean age: 38.2 ± 3.65 age) (Central Mace-
donia). None of the study group and the control group 
members received any dietary supplementation for at 
least 6 months before the analysis.
Blood sample collection
Blood samples were obtained in the morning, before 
transfusional therapy, in EDTA-containing tubes. The 
average monthly transfusion for group A was 4.4  ±  0.5 
times and for group B, 3.2 ± 0.9 times. The samples were 
centrifuged to divide the cellular components from the 
plasma, and stored at -80°C until Trolox Equivalence An-
tioxidant Capacity (TEAC) was carried out.
Measurement of parameters
Antioxidant activity was assayed spectrophotometri-
cally, using a TAC Kit (Total Antioxidant Capacity Colo-
rimetric assay kit, produced by Cayman Chemical Co., 
Ann Arbor, USA) with the TEAC method in the clinical 
chemistry laboratory of the Alexander Technological 
Educational Institute, Thessaloniki, Greece. The levels 
of ferritin in both groups of patients had been measured 
previously by immunoturbidimetry. This technique is 
based on latex bound ferritin antibodies which react with 
the antigen in the sample to form an antigen/antibody 
complex, this is then measured turbidimetrically after 
agglutination. The obtained turbidity is proportional to 
the ferritin concentration and is determined at 700 nm. 
Ferritin determinations were carried out in the biochemi-
cal laboratory of the Saint Paul General Hospital, Thes-
saloniki, Greece. 
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Results 
The results of the study are shown in Tables 2 and 3. 
Plasmatic TAC appeared to be significantly higher in con-
trol subjects compared to the study groups (p = 0.007). 
No correlation existed between TAC and ferritin in 
either of the study groups (r = 0.115; p = 0.546, r = 0.73; 
p = 0.700). Interestingly, there were positive correlations 
in the study subgroups based on their various chelation 
therapies. We observed positive correlations in the mea-
surements of TAC between Italian study subgroups A1 
and A3 (r = 0.682; p = 0.046), and also between A1 and 
B1 (r = 0.681; p = 0.046). Clearly, patients of both coun-
tries that are using deferasirox represent a good model 
of study because of their statistically significant results. 
Indeed, significant results were also observed between 
the ferritin measurements of study subgroups A2 and A3 
(r = 0.663; p = 0.036). Furthermore, a notable inverse cor-
relation was seen between the ferritin levels and age of 
the Italian subgroup A3 (r = -0.775; p = 0.024). Plasmatic 
TAC measurements of the patients under desferriox-
amine showed statistically significant results without any 
statistically significant correlations with ferritin.
Discussion
Oxidative stress in BT patients activates various anti-
oxidant enzyme systems to protect the body tissues from 
its damaging effects. Enzymatic and non-enzymatic anti-
oxidants, either endogenous or exogenous, are known to 
counteract the deleterious effects of ROS (reactive oxy-
gen species) and RNS (reactive nitrogen species), leading 
to protection against oxidative stress and RNS stress. 
ROS formation inside red blood cells (RBCs) is almost 
entirely due to methemoglobin (metHb) formation, but 
under normal steady-state conditions the RBC antioxi-
dant systems can cope with such a threat.12,13 In thalas-
semia, iron mediated ROS formation, originating from 
imbalanced globin production and regular blood transfu-
sions, can cause systemic tissue damage.7,14 Antioxidant 
status can be investigated individually by direct measure-
ment inside the RBC of cytoprotective enzymes such as 
superoxide dismutase (SOD) and glutathione peroxidase 
(GSH-Px).15–18 In our experiments, we chose to measure 
TAC in plasma, as some studies suggest that assessing 
total plasmatic antioxidant capacity is more useful than 
measuring antioxidant individually, since their synergis-
tic interactions could be determined.9,19,20 
In the present study, we measured TAC in Greek and 
Italian patients, considering the high prevalence of BT 
Table 1. Demographical and clinical characteristic of study and control groups
Parameters Italian study group Greek study group Italian controls Greek controls
Thalassemic major patients 30 30 20 20
Age (average) 42 (± 8.9) 41 (± 10.2) 38.2 (± 3.65) 38.75 (± 3.8)
Sex, female/male 19/11 22/8 15/5 16/4
HCV, positive * 2 14 – –
Monthly transfusion 4.4 (± 0.5) 3.2 (± 0.9) – –
Average dosage of Iron chelators (mg/kg) 74.5 (± 32.1) 66.6 (± 30.9) – –
Average years under chelation therapy 33.5 (± 5.8) 37.1 (± 7.07) – –
The values represent mean ± standard error of the mean.
Part 2. Mean Total Antioxidant Capacity and ferritin levels of study group
Study  
groups
Mean TAC 
(mmol/L)  
(n = 30)
Mean ferritin 
(ng/mL)  
(n = 30)
r-value p-value
Italian study 
group
1.83 (± 0.6) 1817 (± 72.2) .115 .546
Greek study 
group
2.42 (± 0.5) 1084 (± 161.15) .73 .700
Mean study 
group*
2.125 (± 0.55) 1450 (± 116.675) – –
*p = 0.007.
Table 2. Mean Total Antioxidant Capacity and ferritin levels of study group 
and control subjects
Part 1. Mean Total Antioxidant Capacity in control subjects
Study  
groups
Mean TAC
(mmol/L)
(n = 20)
Italian controls 2.7 (± 0.7)
Greek controls 3.2 (± 0.5)
Mean controls* 2.95 (± 0.6)
*p = 0.007.
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in these regions as well as the lack of studies analyzing 
and comparing the antioxidant status of patients from 
these Mediterranean countries. A single study by Hamed 
et al. showed a significant decrease in TAC in Italian BT 
patients when compared to normal controls.21 Our study 
confirmed the decreased levels of TAC not only in Ital-
ian but also in Greek BT patients. A different study by 
Bazvand et al., performed in Iranian patients on serum, 
showed increased antioxidant status in BT patients. A 
possible explanation for this unexpected antioxidant sta-
tus detected in Iranian BT patients could be the different 
age range (14.7 ± 6.9) and/or chelation regimen.9
The reduced TAC of BT patients might be due to an 
increased utilization of antioxidants in order to counter-
balance the effects of ROS, which may be involved in the 
pathological consequences of BT major and contribute to 
the gradual development of organ damage.10 The study 
would be strengthened if TAC evaluation was used in 
conjunction with other oxidative stress and antioxidant 
defense biomarkers, such as F2-isoprostanes.26 However 
further investigations are needed in order to gain a better 
understanding about its biological and therapeutic impli-
cations. In particular, prospective studies are needed to 
validate the use of plasmatic TAC in this clinical setting, 
as a useful tool to predict the risk of free radical-induced 
tissue damage. 
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